Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
- PMID: 26774016
- DOI: 10.1016/S1262-3636(16)30005-2
Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
Abstract
Type 2 diabetes is an evolutive disease with a progressive defect of beta-cell insulin secretion. This characteristic points to a need for treatment that takes into account such a natural history. When oral antidiabetic drugs fail to achieve the patient's target HbA1c level, basal insulin treatment is usually initiated and titrated in association with oral drugs to manage fasting hyperglycaemia. Over a period of time, it is enough to simply achieve the HbA1c target. However, when even a good fasting blood glucose level is no longer sufficient to control overall glycaemia, then prandial treatment must be combined with the titrated basal insulin to deal with the postprandial hyperglycaemia responsible for the elevation of HbA1c. Of the different therapeutic options now available for this, rapid-acting insulins and GLP-1 receptor agonists (RAs) can be used. Rapid-acting insulins can be added either at each meal, achieving full insulin supplementation with a basal-bolus regimen, or at the main meal only as a "basal-plus" regimen. Compared with the full basal-bolus, the basal-plus strategy is associated with fewer injections, yet provides similar efficacy in terms of HbA1c improvement, but with less weight gain and lower hypoglycaemic risk. As for GLP-1 RAs, numerous studies, and especially those using short-acting GLP-1 RAs, have demonstrated more pronounced effects on postprandial hyperglycaemia, good complementary effects with basal insulin, and significant improvement of HbA1c with no weight gain and a low risk of hypoglycaemia. Similarly, direct and indirect comparisons of the use of rapid-acting insulins and GLP-1 RAs to intensify basal insulin have shown comparable efficacy in terms of HbA1c control, but with less weight gain and fewer hypoglycaemic episodes with GLP-1 RAs.
Keywords: Basal insulin; GLP-1 receptor agonists; Postprandial hyperglycaemia; Premeal insulin.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.
Similar articles
-
GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.Diabetes Metab. 2015 Dec;41(6 Suppl 1):6S16-6S20. doi: 10.1016/S1262-3636(16)30004-0. Diabetes Metab. 2015. PMID: 26774015
-
Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.Diabetes Care. 2020 Sep;43(9):2303-2312. doi: 10.2337/dc20-0498. Diabetes Care. 2020. PMID: 32910778
-
A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients.Diabetes Obes Metab. 2017 Feb;19(2):216-227. doi: 10.1111/dom.12804. Epub 2016 Nov 29. Diabetes Obes Metab. 2017. PMID: 27717195
-
The rationale for combining GLP-1 receptor agonists with basal insulin.Med J Aust. 2013 Aug 19;199(4):246-9. doi: 10.5694/mja12.11856. Med J Aust. 2013. PMID: 23984780 Review.
-
GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.Diabetes Metab Res Rev. 2019 Jan;35(1):e3082. doi: 10.1002/dmrr.3082. Epub 2018 Oct 18. Diabetes Metab Res Rev. 2019. PMID: 30270567
Cited by
-
Intensification of Basal Insulin Therapy with Lixisenatide in Patients with Type 2 Diabetes in a Real-World Setting: The BASAL-LIXI Study.Curr Ther Res Clin Exp. 2018 Oct 9;89:37-42. doi: 10.1016/j.curtheres.2018.09.001. eCollection 2018. Curr Ther Res Clin Exp. 2018. PMID: 30455779 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials